MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)-based combinations in gastrointestinal (GI) cancers.
Jayesh Desai, Jeremy S Kortmansky, Neil Howard Segal, Marwan Fakih, Do-Youn Oh, Kyu-Pyo Kim, Osama E Rahma, Andrew H Ko, Hyun Cheol Chung, Maria Alsina, Kun-Huei Yeh, Shi Li, Nedal Jaffer Abdulla Al-Sakaff, Jilpa Patel, Hila Barak, Jun Wang, Xiaosong Zhang, Conrad Bleul, Edward Cha, Jeeyun Lee
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019
TPS467 Background: CIT has significant survival benefits across multiple tumor types, but durable response is experienced by only subsets of patients (pts). To extend clinical benefit to more pts, efficacious CIT combinations (combos) targeting multiple cancer immune escape mechanisms need to be identified. The MORPHEUS platform includes multiple ph Ib/II trials designed to identify early signals of safety and efficacy of CIT combos. Using a randomized trial design, multiple treatment (tx) arms are compared with a single control arm in each pt cohort. We present three GI-specific MORPHEUS trials, each assessing CIT combos that could concurrently enhance multiple aspects of the cancer immune..View full abstract